Cyclic depsipeptide as chemotherapeutic anticancer agent
OwnerRicardo Tomas, Beatriz Ramoneda +3inventors
InventorsRicardo Tomas, Beatriz Ramoneda, Ernest Lledo, Marc Pedemonte, Marta Casas
Life of this patent
Estimating the term…
Abstract
Serratamolide, also named cyclo[(3R)-3-hydroxydecanoyl-L-seryl-(3R)-3-hydroxydecanoyl-L-seryl], is a cyclic depsipeptide isolated from cultures of bacteria of the species Serratia marcescens. Serratamolide decreases the viability of, and induces apoptosis in several cancer cells (leukemias, myelomas, carcinomas, etc.), virtually with no effect on non-cancer cells. This makes serratamolide, and its pharmaceutically acceptable addition salts and/or solvates, useful as anticancer chemotherapeutic agent, particularly against leukemia, lymphoma, myeloma, carcinoma, melanoma and sarcoma.
Claims6
A pharmaceutical composition containing a therapeutically effective amount of Serratamolide, or a pharmaceutically acceptable addition salt and/or solvate thereof, for the treatment or prophylaxis of cancer.
A method of use of serratamolide, or of a pharmaceutically acceptable addition salt and/or solvate thereof, for the treatment and/or prophylaxis of cancer.
A pharmaceutical composition for the treatment and/or prophylaxis of cancer, comprising a therapeutically effective amount of serratamolide, or of a pharmaceutically acceptable addition salt and/or solvate thereof, as active principle, together with pharmaceutically acceptable excipients or carriers.
Dependencies are inferred from the claim text.